沙库巴曲缬沙坦治疗慢性心肾综合征的效果和安全性  

Efficacy and safety of sacubitril-valsartan in the treatment of chronic cardiorenal syndrome

作　　者：薛渊[1] 李平[1] 吴玉彩[1] 王念华[1] 沈实现[1] Xue Yuan;Li Ping;Wu Yucai;Wang Nianhua;Shen Shixian(Department of Nephrology,Puyang People’s Hospital,Puyang 457000,China)

机构地区：[1]濮阳市人民医院肾内科,濮阳457000

出　　处：《中国实用医刊》2023年第5期102-105,共4页Chinese Journal of Practical Medicine

摘　　要：目的分析沙库巴曲缬沙坦治疗慢性心肾综合征的效果和安全性。方法抽取2020年5月至2022年5月濮阳市人民医院收治的慢性心肾综合征患者72例,根据治疗方案将患者分为对照组(35例)与观察组(37例)。对照组采用常规治疗,观察组在对照组治疗基础上加用沙库巴曲缬沙坦治疗,两组均治疗3个月。比较两组患者的临床疗效、心功能指标[左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)]、肾功能指标[脑钠肽(BNP)、血清尿素氮(BUN)、肾小球滤过率(GFR)、血肌酐(Scr)]以及不良反应发生情况。结果观察组临床总有效率(91.89%,34/37)高于对照组(71.43%,25/35),差异有统计学意义(P<0.05)。治疗前,两组LVEF、LVEDD及LVESD比较差异未见统计学意义(P>0.05);治疗后,两组LVEF均高于治疗前,LVEDD及LVESD均低于治疗前,且观察组改善幅度优于对照组(P<0.05)。治疗前,两组BNP、BUN、GFR及Scr水平比较差异未见统计学意义(P>0.05);治疗后,两组BNP、BUN、GFR及Scr水平均明显改善,且观察组改善幅度优于对照组(P<0.05)。观察组不良反应发生率(8.11%,3/37)与对照组(14.28%,5/35)比较差异未见统计学意义(P>0.05)。结论慢性心肾综合征患者采用沙库巴曲缬沙坦治疗,可以有效改善患者的心、肾功能,效果确切,安全性高。Objective To analyze the efficacy and safety of sacubitril-valsartan in the treatment of chronic cardiorenal syndrome.Methods A total of 72 patients with chronic cardiorenal syndrome admitted to Puyang People’s Hospital from May 2020 to May 2022 were selected,and they were divided into control group(35 cases)and observation group(37 cases)according to treatment scheme.The control group was treated by conventional therapy,and the observation group was treated with sacubitril-valsartan based on the treatment of the control group.Both groups were treated for 3 months.The clinical efficacy,cardiac function indexes including left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD),renal function assessed by brain natriuretic peptide(BNP),blood urea nitrogen(BUN),glomerular filtration rate(GFR)and serum creatinine(Scr),and adverse reactions of the two groups were compared.Results The total effective rate of the observation group(91.89%,34/37)was higher than that of the control group(71.43%,25/35),and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in LVEF,LVEDD and LVESD between the two groups(P>0.05).After treatment,LVEF in both groups were higher than those before treatment,while LVEDD and LVESD were lower than those before treatment,and the improvement of the observation group was better than that of the control group(P<0.05).Before treatment,there was no statistically significant difference in levels of BNP,BUN,GFR and Scr between the two groups(P>0.05).After treatment,the levels of BNP,BUN,GFR and Scr in the two groups were significantly improved,and the improvement of the observation group was better than that of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the observation group(8.11%,3/37)and the control group(14.28%,5/35),P>0.05.Conclusions Sacubitril-valsarta in the treatment of patients with chronic cardiorena

关 键 词：心肾综合征 沙库巴曲缬沙坦 心功能 肾功能 安全性 

分 类 号：R541.6[医药卫生—心血管疾病] R692.5[医药卫生—内科学]